FSAP is elavated in pregnancy and in women using OCs

Parahuleva et al. analyzed whether pregnancy or the use of oral contraceptives (OCs) influences circulating FSAP levels. FSAP levels and activity was measured in plasma samples obtained at different gestation stages from healthy pregnant women, from non-pregnant, pre-menopausal women who currently use OCs, and who did not use OCs. Plasma FSAP antigen and activity level was [...]

Hormon therapy increases FSAP antigen and activiy

Recent studies indicate that FSAP may play roles in the development and expression of atherosclerosis and that FSAP can be involved in the precipitation of coronary heart disease. It was demonstrated, that hormone therapy (HT) has a protective role in coronary heart disease (CHD) in younger postmenopausal women, whereas hormone therapy contributes to coronary heart [...]

Effect of oral contraceptives on FSAP

Oral contraceptives (OCs) affect plasma levels of haemostatic factors and the use of OC is a risk factor for development of cardiovascular disease. This study addressed the effect of OCs on FSAP in human blood. Women were analysed that took oral contraceptives with different estrogen and progestin dosage. Marburg I variant, FSAP antigen and FSAP activity [...]

Factor VII-Activating Protease (FSAP) in atherosclerotic plaques

FSAP was studied at the protein level (immuno-histochemistry) and the mRNA level (PCR) in atherosclerotic lesions obtained by directional coronary atheroectomy. Higher levels of FSAP mRNA (p<0,001) as well as FSAP antigen (p<0,005) were observed in patients with acute coronary syndromes compared to patients with stable angina pectoris. FSAP was also found to be co-localized [...]

Factor VII-Activating Protease Marburg I variant and carotid stenosis

Willeit and colleagues analysed the impact of FSAP polymorphism on the evolution and progression of carotid stenosis. They used an ultrasound model of atherosclerosis progression which can differentiate early from advanced stages of vessel disease. 810 men and women between 40 and 79 years (from the so-called “Bruneck” study”) were studied. No correlation was found [...]

Factor VII-Activating Protease Marburg I variant and cardiovascular risk

In their “Northwick Park Heart Study II” Ireland and colleagues addressed the risk for coronary disease in a prospective study of cardiovascular disorders. They found an interactive effect upon risk between the FSAP G511E allele and elevated levels of cholesterol, triglyeride, or fibrinogen. This was taken to conclude that “…the FSAP G511E allele exacerbates atherosclerosis [...]

Factor VII-Activating Protease and Liver Cirrhosis

Wasmuth and colleagues addressed the fact that genetic factors affect the progression of liver fibrosis in chronic hepatitis C (HCV) infection and they asked whether the Marburg I variant of FSAP (FSAP G511E allele) might play a role. Their findings suggest that the G511E variant is a risk locus for HCV-induced liver fibrosis and cirrhosis. [...]